Sigilon Therapeutics SGTX Stock
Sigilon Therapeutics Price Chart
Sigilon Therapeutics SGTX Financial and Trading Overview
| Sigilon Therapeutics stock price | 22.47 USD |
| Previous Close | 4.52 USD |
| Open | 4.8 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 900 |
| Day's Range | 4.44 - 5.15 USD |
| 52 Week Range | 3.77 - 20.93 USD |
| Volume | 10.09K USD |
| Avg. Volume | 7.52K USD |
| Market Cap | 12.66M USD |
| Beta (5Y Monthly) | 0.822452 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.67 USD |
SGTX Valuation Measures
| Enterprise Value | -19590366 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.46895275 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.8649084 |
| Price/Book (mrq) | 0.380251 |
| Enterprise Value/Revenue | -1.338 |
| Enterprise Value/EBITDA | 0.542 |
Trading Information
Sigilon Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.822452 |
| 52-Week Change | -54.52% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 20.93 USD |
| 52 Week Low | 3.77 USD |
| 50-Day Moving Average | 6.95 USD |
| 200-Day Moving Average | 7.77 USD |
SGTX Share Statistics
| Avg. Volume (3 month) | 7.52K USD |
| Avg. Daily Volume (10-Days) | 7.24K USD |
| Shares Outstanding | 2.5M |
| Float | 1.33M |
| Short Ratio | 0.78 |
| % Held by Insiders | N/A |
| % Held by Institutions | N/A |
| Shares Short | 8.85K |
| Short % of Float | 0.52% |
| Short % of Shares Outstanding | 0.34% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:13 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -253.33% |
| Operating Margin (ttm) | -255.76% |
| Gross Margin | -130.88% |
| EBITDA Margin | -247.13% |
Management Effectiveness
| Return on Assets (ttm) | -23.080% |
| Return on Equity (ttm) | -75.76% |
Income Statement
| Revenue (ttm) | 14.64M USD |
| Revenue Per Share (ttm) | 5.87 USD |
| Quarterly Revenue Growth (yoy) | 53.50% |
| Gross Profit (ttm) | -24687000 USD |
| EBITDA | -36173000 USD |
| Net Income Avi to Common (ttm) | -37080000 USD |
| Diluted EPS (ttm) | -15.61 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 56.37M USD |
| Total Cash Per Share (mrq) | 22.53 USD |
| Total Debt (mrq) | 25.47M USD |
| Total Debt/Equity (mrq) | 76.5 USD |
| Current Ratio (mrq) | 2.23 |
| Book Value Per Share (mrq) | 13.307 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -43388000 USD |
| Levered Free Cash Flow (ttm) | -31713750 USD |
Profile of Sigilon Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 100 Binney Street |
| ZIP | 02142 |
| Phone | (617) 336-7540 |
| Website | https://sigilon.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 62 |
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Q&A For Sigilon Therapeutics Stock
What is a current SGTX stock price?
Sigilon Therapeutics SGTX stock price today per share is 22.47 USD.
How to purchase Sigilon Therapeutics stock?
You can buy SGTX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Sigilon Therapeutics?
The stock symbol or ticker of Sigilon Therapeutics is SGTX.
Which industry does the Sigilon Therapeutics company belong to?
The Sigilon Therapeutics industry is Biotechnology.
How many shares does Sigilon Therapeutics have in circulation?
The max supply of Sigilon Therapeutics shares is 2.5M.
What is Sigilon Therapeutics Price to Earnings Ratio (PE Ratio)?
Sigilon Therapeutics PE Ratio is 0.00000000 now.
What was Sigilon Therapeutics earnings per share over the trailing 12 months (TTM)?
Sigilon Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Sigilon Therapeutics company belong to?
The Sigilon Therapeutics sector is Healthcare.
Sigilon Therapeutics SGTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}